Skip to main content
Caplight Logo









HemaChrome

HemaChrome

Private
West Lafayette, IndianaHealthcare & Life Scienceshttps://www.hemachrome.co/

Last Round

Grant

Feb 15, 2023

Total Funding Raised

$425,000

Company Overview

HemaChrome is a digital health company that provides a non-invasive smartphone-based platform for measuring blood hemoglobin levels.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Telemedicine, Clinical Trials, Computer Vision

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

noninvasive hemoglobin testinganemia screeningdigital healthpoint-of-care diagnosticsremote patient monitoringhyperspectral imagingcomputer visionmHealthsmartphone diagnosticsAI diagnosticstelemedicinemedical device softwareSaMDclinical decision supportdigital biomarker

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HemaChrome Comparables

Compare HemaChrome with similar companies based on industry and business-model similarity.

HemaChrome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Monere
88%
Sanguina, Inc.
84%
EzeRx Health Tech
70%

HemaChrome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 15, 2023
AcceleratorNov 8, 2021
GrantNov 4, 2020

HemaChrome Investors

Notable investors and investment history

HemaChrome investors
InvestorRounds
National Institute of Biomedical Imaging and BioengineeringGrant
NIH RADxGrant
Purdue FoundryAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 15, 2023

    $20K grant received from NIH RADx.

  • Nov 4, 2020

    $400K grant from the National Institute of Biomedical Imaging and Bioengineering.

HemaChrome Filings

Explore SEC and related filing metadata, where available.

HemaChrome filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about HemaChrome's valuation, stock price, and market status.

Is HemaChrome a public or private company?

HemaChrome is a private company.

What is the current stock price of HemaChrome?

HemaChrome is a private company with no public stock price. No recent secondary market data is available.

How much is HemaChrome worth (valuation)?

Valuation information for HemaChrome is not publicly available.

Can I buy HemaChrome stock?

HemaChrome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was HemaChrome's last funding round?

HemaChrome's most recent funding round was Grant on February 15, 2023.

Who are the main investors in HemaChrome?

Key investors in HemaChrome include National Institute of Biomedical Imaging and Bioengineering, NIH RADx, Purdue Foundry.

Will HemaChrome IPO soon?

No public IPO plans have been announced for HemaChrome.

How can I track HemaChrome secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor HemaChrome's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWest Lafayette, Indiana
Year Founded2019
Last FundingFeb 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?